All In Biotech

Drug Trial Radar · NCT02531815

Dose Escalation Study of PF-06741086 In Healthy Subjects

A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects

Last checked: Nov 20, 2026Latest source record: Aug 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Aug 2015

Primary completion

Jul 2016

Study completion Jul 2016

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 25, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.

Conditions

  • Healthy

Interventions

  • PF-06741086Biological

    PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)

  • PlaceboDrug

    Placebo for PF-06741086, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEsTime frame: Day 1 up to Day 84
  2. Percentage of subjects with laboratory abnormalitiesTime frame: Day 1 up to Day 84
  3. Number of subjects with change from baseline in vital signsTime frame: Day 1 up to Day 84
  4. Number of subjects with change from baseline in electrocardiogram (ECG) parametersTime frame: Day 1 to Day 84
  5. Percentage of subjects with changes from baseline in physical examinationTime frame: Day 1 to Day 84
  6. Percentage of subjects with infusion site reactionsTime frame: Day 1 up to Day 7
  7. Percentage of subjects with injection site reactionsTime frame: Day 1 to Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Clinical Research Unit

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.